重症医学整群随机对照试验的理论依据、方法学质量与报告:一项系统评价
该系统评价检索Medline、Embase和Cochrane Central Register,纳入2005年1月至2019年9月在成人、儿科或新生儿重症监护病房开展的整群随机对照试验,共59项符合标准。多数聚焦质量改进(24项,41%)、抗微生物治疗(9项,15%)或感染控制(9项,15%)干预;设计包括平行组(25项,42%)、交叉(21项,36%)和阶梯楔形(13项,22%)。分配隐藏仅21项(36%)报告,13项(22%)报告至少一种盲法;样本量计算报告率90%,但仅54%符合CONSORT样本量报告要求;46%在试验开始前确定可用集群固定数量,仅15%同时预设集群数和患者数;75%在主要结局分析中适当调整集群效应,仅20%报告集群内相关系数(中位数0.047)。结论认为关键方法学方面报告常不充分。
要点
- 59项整群随机对照试验中,分配隐藏仅21项(36%)报告,13项(22%)报告至少一种盲法。
- 样本量计算报告率90%,但仅54%符合CONSORT样本量报告要求;68%(36项)达到预设总样本量。
- 46%在试验开始前确定可用集群固定数量,仅15%(9项)同时预设集群数和患者数。
- 75%(44项)在主要结局分析中适当调整集群效应,仅20%(12项)报告集群内相关系数(中位数0.047)。
- 集群数中位数12(IQR 5-24),每集群患者数中位数141(IQR 54-452),总样本量中位数1,660例(IQR 813-4,295)。
适用人群与场景
- 2005年1月至2019年9月在成人、儿科或新生儿重症监护病房开展的整群随机对照试验。
研究设计与关键结果
- 系统评价共检索1,902条引文,最终纳入59项整群随机对照试验。
- 干预类型:质量改进24项(41%)、抗微生物治疗9项(15%)、感染控制9项(15%)。
- 设计类型:平行组25项(42%)、交叉21项(36%)、阶梯楔形13项(22%)。
- 分配隐藏报告21项(36%),至少一种盲法报告13项(22%)。
- 总样本量中位数1,660例(IQR 813-4,295),集群数中位数12(IQR 5-24),每集群患者数中位数141(IQR 54-452)。
- 样本量计算报告90%,符合CONSORT样本量报告指南仅54%;46%(27项)在试验开始前确定可用集群固定数量,仅15%(9项)同时预设集群数和患者数。
- 68%(36项)达到预设总样本量;75%(44项)在主要结局分析中适当调整集群效应;20%(12项)报告集群内相关系数(中位数0.047,IQR 0.01-0.13)。
证据类型、等级与局限
- 证据类型:系统评价。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为重症医学整群随机对照试验通常涉及数量少且固定的较大集群,这些试验关键方法学方面的报告常不充分。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Compared with individual-patient randomized controlled trials, cluster randomized controlled trials have unique methodological and ethical considerations. We evaluated the rationale, methodological quality, and reporting of cluster randomized controlled trials in critical care studies.
DATA SOURCES: Systematic searches of Medline, Embase, and Cochrane Central Register were performed.
STUDY SELECTION: We included all cluster randomized controlled trials conducted in adult, pediatric, or neonatal critical care units from January 2005 to September 2019.
DATA EXTRACTION: Two reviewers independently screened citations, reviewed full texts, protocols, and supplements of potentially eligible studies, abstracted data, and assessed methodology of included studies.
DATA SYNTHESIS: From 1,902 citations, 59 cluster randomized controlled trials met criteria. Most focused on quality improvement (24, 41%), antimicrobial therapy (9, 15%), or infection control (9, 15%) interventions. Designs included parallel-group (25, 42%), crossover (21, 36%), and stepped-wedge (13, 22%). Concealment of allocation was reported in 21 studies (36%). Thirteen studies (22%) reported at least one method of blinding. The median total sample size was 1,660 patients (interquartile range, 813-4,295); the median number of clusters was 12 (interquartile range, 5-24); and the median patients per cluster was 141 (interquartile range, 54-452). Sample size calculations were reported in 90% of trials, but only 54% met Consolidated Standards of Reporting Trials guidance for sample size reporting. Twenty-seven of the studies (46%) identified a fixed number of available clusters prior to trial commencement, and only nine (15%) prespecified both the number of clusters and patients required to detect the expected effect size. Overall, 36 trials (68%) achieved the total prespecified sample size. When analyzing data, 44 studies (75%) appropriately adjusted for clustering when analyzing the primary outcome. Only 12 (20%) reported an intracluster coefficient (median 0.047 [interquartile range, 0.01-0.13]).
CONCLUSIONS: Cluster randomized controlled trials in critical care typically involve a small and fixed number of relatively large clusters. The reporting of key methodological aspects of these trials is often inadequate.
参考来源
- Cook DJ, Rutherford WB, Scales DC, et al. Rationale, Methodological Quality, and Reporting of Cluster-Randomized Controlled Trials in Critical Care Medicine: A Systematic Review. Crit Care Med. 2021. PMID: 33591020. doi:10.1097/CCM.0000000000004885
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。